The role of HSD17B11 in (S)–3 cytotoxic activity was further confirmed using two different small-interfering RNAs (siRNA) to down-regulate HSD17B11 in U2OS (Figure 1—figure supplement 5E, F) and in the non-small cell lung carcinoma cell line A549, in which CRISPR/Cas9-mediated HSD17B11 inactivation also conferred (S)–3 resistance (Figure 1—figure supplement 5G,H). This evidence concerns the gene HSD17B11 and non-small cell lung carcinoma.